Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 33 | 1,112 | 40% |
| 2020 | 17 | 818 | 43% |
| 2021 | 20 | 911 | 48% |
| 2022 | 22 | 887 | 52% |
| 2023 | 26 | 930 | 56% |
| 2024 | 27 | 1,005 | 59% |
| 2025 from claims | – | 898 824–950 | 61% |
| 2026 forecast | – | 912 803–1,053 | 62% |
| 2027 forecast | – | 923 789–1,100 | 62% |
| 2028 forecast | – | 934 779–1,143 | 63% |
| 2029 forecast | – | 944 771–1,184 | 64% |
| 2030 forecast | – | 953 764–1,222 | 65% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 59% of the cases CMS names in North Carolina; 18 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 55% hospital outpatient, 45% surgery center. The share outside the hospital has moved +31 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~910 | ~490 | ~430 |
| 2027 · ~920 | ~490 | ~440 |
| 2028 · ~930 | ~490 | ~440 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 48% (45% in 2025), hospital outpatient about 52% (55% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 99 | 3,368+0.4%/yr | +0.4%/yr | 1.4 | 71% | 4,030 in 2030+3.1%/yr |
| Florida | 48 | 1,901−2%/yr | −2%/yr | 0.8 | 65% | 2,240 in 2030+2.8%/yr |
| Tennessee | 22 | 830+1.8%/yr | +1.8%/yr | 1.1 | 70% | 1,040 in 2030+3.9%/yr |
| Georgia | 17 | 798−4.7%/yr | −4.7%/yr | 0.8 | 69% | 850 in 2030+1.1%/yr |
| Oklahoma | 21 | 734−3%/yr | −3%/yr | 1.4 | 45% | 850 in 2030+2.5%/yr |
| South Carolina | 21 | 702−4.7%/yr | −4.7%/yr | 1.0 | 36% | 710 in 2030+0.1%/yr |
| Maryland | 13 | 599+6.8%/yr | +6.8%/yr | 0.7 | 87% | 820 in 2030+5.5%/yr |
| Virginia | 13 | 494−4.5%/yr | −4.5%/yr | 0.4 | 18% | 600 in 2030+3.3%/yr |
| Louisiana | 10 | 385−5.1%/yr | −5.1%/yr | 0.9 | 52% | 420 in 2030+1.4%/yr |
| Mississippi | 10 | 380−3%/yr | −3%/yr | 1.0 | 72% | 490 in 2030+4.5%/yr |
| Kentucky | 7 | 342−3.7%/yr | −3.7%/yr | 0.7 | 42% | 480 in 2030+5.7%/yr |
| Arkansas | 11 | 302−2.5%/yr | −2.5%/yr | 0.7 | 51% | 330 in 2030+1.3%/yr |
| Alabama | 4 | 201−12%/yr | −12%/yr | 0.4 | 35% | 180 in 2030−1.6%/yr |
| West Virginia | 1 | 120−14%/yr | −14%/yr | 0.5 | 0% | 120 in 2030+0.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 172 | 11,392−0.4%/yr | −0.4%/yr | 10.90.8× | 82% | 12,200 in 2030+1.2%/yr |
| Peripheral nerve stimulation & intrathecal pumps | 21 | 1,154+13%/yr | +13%/yr | 1.10.8× | 42% | 1,560 in 2030+5.2%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Texas
Boston Scientific leads with 28% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 10 companies reported engagement with North Carolina’s surgeons worth $710K in consulting, speaking, meals and travel tied to these products, about $26K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 63685 (ins/rplc spi npg/rcvr pocket), commercial plans pay North Carolina’s hospitals a median of $30K, from $8,189 at the lowest to $30K at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.